BridgeBio Pharma reported second quarter 2026 financial results showing total revenues of $243.7 million, driven by $222.4 million in U.S. Attruby net product revenue. The company closed a $1 billion preferred equity financing on July 1, 2026, and holds $720.2 million in cash as of June 30, 2026. Regulatory milestones include FDA acceptance with Priority Review for BBP-418 (PDUFA November 27, 2026), encaleret (PDUFA May 8, 2027), and the submission of an NDA for oral infigratinib. The company operates as a commercial-stage biopharmaceutical firm developing medicines for genetic conditions.
